A structure-function approach to optimizing TLR4 ligands for human vaccines
about
Not All Antigens Are Created Equally: Progress, Challenges, and Lessons Associated with Developing a Vaccine for Leishmaniasis.Alternative to Chemotherapy-The Unmet Demand against Leishmaniasis.Translating Observations From Leishmanization Into Non-Living Vaccines: The Potential of Dendritic Cell-Based Vaccination Strategies Against Leishmania.Control of Heterologous Simian Immunodeficiency Virus SIV Infection by DNA and Protein Coimmunization Regimens Combined with Different Toll-Like-Receptor-4-Based Adjuvants in MacaquesA combination of TLR-4 agonist and saponin adjuvants increases antibody diversity and protective efficacy of a recombinant West Nile Virus antigenHeterologous Immunization With Defined RNA and Subunit Vaccines Enhances T Cell Responses That Protect Against
P2860
A structure-function approach to optimizing TLR4 ligands for human vaccines
description
2016 nî lūn-bûn
@nan
2016 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
A structure-function approach to optimizing TLR4 ligands for human vaccines
@ast
A structure-function approach to optimizing TLR4 ligands for human vaccines
@en
type
label
A structure-function approach to optimizing TLR4 ligands for human vaccines
@ast
A structure-function approach to optimizing TLR4 ligands for human vaccines
@en
prefLabel
A structure-function approach to optimizing TLR4 ligands for human vaccines
@ast
A structure-function approach to optimizing TLR4 ligands for human vaccines
@en
P2093
P2860
P50
P356
P1476
A structure-function approach to optimizing TLR4 ligands for human vaccines
@en
P2093
Anthony Desbien
Christopher B Fox
Greg Ireton
Hong Liang
Jeffrey A Guderian
Julie Vergara
Malcolm S Duthie
Rhea N Coler
Tracey A Day
P2860
P2888
P356
10.1038/CTI.2016.63
P407
P577
2016-11-01T00:00:00Z
P6179
1001873015